{
    "nctId": "NCT03497702",
    "briefTitle": "Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer",
    "officialTitle": "Phase II Study of Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer, Invasive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 114,
    "primaryOutcomeMeasure": "pathologic complete remission (pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Pathologically proven breast cancer patients who are candidate of neoadjuvant chemotherapy with AC followed by Docetaxel\n* Age: 19-70 years\n* ER or PR positive ,cT2-3N0 or cT1-3/N+ M0 (ER-positive \u22651% nuclear staining by immunohistochemistry , Allred score\u22653 )\n* Available FFPE tissue for biomarker study\n* HER2-negative by ASCO/CAP guideline\n* Patients who agree to adequate contraception\n* ECOG scores of 0-2\n* Normal or acceptable kidney, liver, cardiovascular, and bone marrow functions\n* Patients who provide consent\n\nExclusion Criteria:\n\n* Inflammatory breast cancer\n* Distant metastasis\n* Cerebral vascular accidents including transient ischemic attack\n* Pulmanary thromboembolism or deep vein thrombosis with 6 months; however, patients who received more than 6 weeks of anticoagulation within 6 months and remains asymptomatic are eligible.\n* With a history of malignant tumor or complicated with other malignant tumors in addition to breast cancer, except for non-melanoma skin cancer, curatively resected early gastric cancer, differentiated thyoid cancer \\< 1 cm, or other cured malignant tumor without recurrence for at least 3 years\n* Ejection Fraction \\<55% by MUGA scan / Echo CG\n* No available tissue for biomarker study\n* Pregnant or lactating women\n* Patients with other serious diseases or medical conditions: Pituitary adenoma, Malabsorption syndrome, Major resection of gastrointestinal tract, Corrected QT interval \\> 480 msec, Congestive heart failure or unstable angina pectoris, myocardial infarction, stent insertion, angioplasty, coronary bypass surgery, symptomatic peripheral artery disease within 6 months before the enrollment\n* NYHA class III or IV congestive heart failure\n* Uncontrolled hypertension and uncontrolled high-risk arrhythmia considered by the investigator\n* Major surgery, major trauma, and/or unhealed wound, fracture, or ulcer within 4 weeks\n* Acute hemorrhage or hemorrhagic tendency\n* Obvious neurological or psychiatric disorders, including psychosis, epileptic dementia and other diseases which may affect the understanding and sign of the informed consent\n* Uncontrolled acute infection\n* Patients with allergic constitution and any known or suspected drug allergy\n* Concurrent use of other investigational drugs; or participating in other clinical trials involving investigational drugs within 30 days before this study\n* Patients with mental illness or other conditions affecting the patient compliance\n* Not suitable for the trial considered by the investigator",
    "sex": "FEMALE",
    "minimumAge": "19 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}